ToxStrategies toxicologist Dr. Rayetta Henderson served on a panel that briefed both the U.S. House and Senate on the future regulation of CBD as a dietary supplement. Dr. Henderson’s presentation focused on her recent study deriving recommended upper intake limits for CBD and the need for evidence-based guidance for consumers. The panel members followed the briefings with a livestream webinar that discussed the current regulatory status of CBD and key considerations for future FDA regulation. The recorded webinar can be viewed here.
L-R: Rayetta Henderson, ToxStrategies LLC; Kelly D. Fair, Dentons; Page Figi, COALITION FOR ACCESS NOW; Jennifer Baxter, Balanced Veterans Network; Nicole Hemmenway, U.S. Pain Foundation